Robert D. Bajefsky and Gregory Chopskie of the intellectual property law firm Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., examine several court rulings which implicate generic drug makers in actions designed to seek advantage in the complex process of copying and marketing prescription drugs once their patent protection expires.